Wikipedia
Olaratumab
Olaratumab is a monoclonal antibody which is being developed by Imclone for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
In February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft tissue sarcoma.